Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)
ID: RFA-DA-25-052Type: BOTH
Overview

Topic

Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2024

Topic Link

https://www.sbir.gov/node/2486901

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-052.html
Timeline
  1. 1
    Release Oct 25, 2023 12:00 AM
  2. 2
    Open Feb 14, 2024 12:00 AM
  3. 3
    Next Submission Due Mar 14, 2024 12:00 AM
  4. 4
    Close Mar 15, 2024 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for tools to support decentralized clinical trials for substance use disorder (SUD). Traditional SUD clinical trials require in-person visits, which can limit participation and retention due to factors such as travel time, stigma, and childcare responsibilities. Decentralized clinical trials (DCT) offer a solution by utilizing telehealth visits, remote monitoring, and local medication dispensing. However, there are gaps in the technology needed for DCT, such as wearable sensors for physiological measurement and a comprehensive system for secure data sharing and communication. The goal of this solicitation is to develop tools for DCT that increase participation, diversity, and retention in SUD clinical trials. The research and development areas of interest include wearable devices for drug measurement, socially acceptable devices for SUD trials, software solutions for data handling, and systems that can operate in low-bandwidth or rural areas. The Small Business Innovation Research (SBIR) program offers Phase I, Fast Track, and Direct-to-Phase II funding opportunities for eligible applicants. The application due date for this solicitation is March 14, 2024. For more information, visit the SBIR topic link (https://www.sbir.gov/node/2486901) or the solicitation agency URL (https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-052.html).

Files
No associated files provided.
Similar Opportunities
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Phase II applications, including Fast-Track applications that combine both phases. The deadline for submission is March 14, 2026. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html).
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Fast-Track (Phase I/Phase II) applications, with a focus on establishing technical feasibility and commercial potential. The application due date is March 13th, 2024, with subsequent due dates in 2025 and 2026. More information can be found on the grants.gov website.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The purpose of this funding opportunity is to support small business concerns in developing technologies for commercialization that can fill the service gaps in addressing SUD. The research objectives include developing products that reduce costs, time, and increase access in addressing health-related social needs such as housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The technologies can include physical devices, digital services, software, or non-physical/non-tangible products. The funding opportunity is open for applications until March 14, 2026, and offers both Phase I and Phase II funding options. Phase I focuses on establishing technical merit and feasibility, while Phase II aims to advance technologies towards commercialization. Applicants are encouraged to review the guidelines and adhere to the requirements applicable to their research.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis surrounding OUD/StUD is a significant issue, with over 100,000 overdose deaths reported in a one-year period. The goal of this solicitation is to offer new medical products that can monitor, diagnose, and treat patients suffering from these disorders. The solicitation is open to small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space. The research and development activities may fall into two areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The proposed projects should aim to address the needs of patients suffering from OUD/StUD and may include activities such as target identification, lead optimization, preclinical studies, formulation development, and clinical trials. The funding for these projects will be provided through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding available. The application due dates are August 15, 2023, February 14, 2024, August 13, 2024, and February 14, 2025. For more information and to apply, interested parties can visit the grants.gov website or the solicitation agency URL provided.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.